https://www.selleckchem.com/pr....oducts/almorexant-hc
1%). Seven patients (50%) required one session of embolization, 4 patients (28.6%) required two, 2 patients (14.3%) required three and 1 patient (7.1%) required four sessions. Complete nidus exclusion was achieved in 11 patients (78.6%), optimal clinical response in 12 patients (85.7%). Four patients (28.6%) exhibited minor complications, all controlled. No major complications were seen. Four patients underwent surgical intervention (28.6%). The embolization of peripheral AVM with NALA in DLB appears to be safe and feasible, achi
Like
Comment
Share
